Actinium (Ac 225) Oxodotreotide

Actinium (Ac 225) Oxodotreotide, also known as RYZ101, is being investigated in clinical trials for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This article provides an overview of the ongoing research, including the trial’s objectives, eligibility criteria, and potential benefits for patients who have progressed after previous treatments.

Related diseases and areas:

• Gastroenteropancreatic neur…

Adagrasib

Clinical trials are studying Adagrasib in people with KRAS G12C-mutant cancers, mainly non-small cell lung cancer and colorectal cancer. These studies look at how well it works, how safe it is, and whether it helps when used alone or with other cancer treatments. The trials include people with advanced, untreated, or previously treated disease.

Related diseases and areas:

• Colorectal cancer
• Non-small cell lung cancer …
• K-ras gene mutation
• Colorectal cancer metastatic
• Non-small cell lung cancer …
• Non-small cell lung cancer …

ADCE-D01

Clinical trials are investigating ADCE-D01 in people with soft tissue sarcoma. These studies are looking at safety, tolerability, and whether the treatment may help shrink tumors. The trial includes adults in early and later study phases.

Related diseases and areas:

• Soft tissue sarcoma

Adct-402

Clinical trials investigating Adct-402 are studying it in people with previously untreated diffuse large B-cell lymphoma and related B-cell lymphomas. The main goal is to assess how well the treatment works and how well it is tolerated in unfit or frail patients, including those with heart problems.

Related diseases and areas:

• Diffuse large B-cell lymphoma

Adeno-Associated Viral Vector Serotype 2 Encoding Glial Cell Line-Derived Neurotrophic Factor

This article discusses the clinical trials of AAV2-GDNF, a novel gene therapy treatment for moderate Parkinson’s disease. AAV2-GDNF is an adeno-associated viral vector that delivers the gene for glial cell line-derived neurotrophic factor (GDNF) to the brain. The therapy aims to improve or stabilize motor and non-motor symptoms in patients with moderate Parkinson’s disease. We’ll explore the key aspects of the ongoing clinical trial, including its objectives, eligibility criteria, and potential benefits for patients.

Related diseases and areas:

• Parkinson’s disease

Adeno-Associated Viral Vector Serotype 2.7M8 Containing The Chrimsonr-Tdtomato Gene

This article discusses ongoing clinical trials investigating the use of a novel gene therapy, GS030-DP, for treating Retinitis Pigmentosa. The therapy utilizes an Adeno-Associated Viral Vector Serotype 2.7M8 containing the ChrimsonR-tdTomato gene. These trials aim to evaluate the safety, tolerability, and potential effectiveness of this innovative approach in patients with non-syndromic Retinitis Pigmentosa, a genetic eye disorder causing progressive vision loss.

Related diseases and areas:

• Retinitis pigmentosa

Adeno-Associated Viral Vector Serotype 2/8 Containing The Human Ugt1A1 Gene

Recent clinical trials are investigating the use of an innovative gene therapy, Adeno-Associated Viral Vector Serotype 2/8 Containing The Human UGT1A1 Gene (GNT0003), for patients with severe Crigler-Najjar syndrome. This rare genetic disorder affects the liver’s ability to process bilirubin, leading to potentially severe complications. The trials aim to evaluate the safety, efficacy, and long-term impact of this groundbreaking treatment approach, offering hope for patients who currently rely on daily phototherapy.

Related diseases and areas:

• Crigler-Najjar syndrome

Adeno-Associated Viral Vector Serotype 3B Encoding Shortened Human Atp7B

This article provides an overview of a clinical trial investigating the use of VTX-801, a gene therapy drug containing an Adeno-Associated Viral Vector Serotype 3B Encoding Shortened Human ATP7B, for the treatment of Wilson’s Disease. The trial aims to assess the safety, tolerability, and potential effectiveness of this innovative approach in adult patients with Wilson’s Disease.

Related diseases and areas:

• Hepato-lenticular degeneration

Adeno-Associated Viral Vector Serotype 8 Containing The 3′-Myo7A Gene Coding Sequence

This article discusses an ongoing clinical trial investigating the use of AAVB-081, a novel gene therapy treatment for Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa. AAVB-081 is an adeno-associated viral vector designed to deliver the MYO7A gene to the retina. The study aims to assess the safety, tolerability, and potential effectiveness of this innovative approach in treating this rare genetic eye disorder.

Related diseases and areas:

• Usher’s syndrome

Adeno-Associated Viral Vector Serotype 8 Containing The 5′-Myo7A Gene Coding Sequence

This article discusses an ongoing clinical trial investigating the use of AAVB-081, a novel gene therapy treatment for Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa. AAVB-081 is an innovative approach using adeno-associated viral vectors to deliver the MYO7A gene, potentially addressing the underlying genetic cause of this rare inherited eye disorder. The trial aims to assess the safety, tolerability, and efficacy of this groundbreaking treatment, offering hope for patients with this debilitating condition.

Related diseases and areas:

• Usher’s syndrome

Adeno-Associated Viral Vector Serotype 8 Containing The Human Cnga3 Gene Under The Control Of A Cone Arrestin Promoter

A groundbreaking clinical trial is underway to investigate the safety and effectiveness of a new gene therapy treatment for CNGA3-linked achromatopsia, a rare genetic eye disorder. The study, named “Colour Bridge,” focuses on the use of rAAV.hCNGA3, an adeno-associated viral vector containing the human CNGA3 gene. This treatment is administered through a single subretinal injection in both eyes of adult and minor patients. The trial aims to evaluate how this innovative approach may potentially improve vision in individuals with this specific form of color blindness.

Related diseases and areas:

• Colour blindness

Adeno-Associated Viral Vector Serotype 8 Containing The Human Md1 Gene

A groundbreaking clinical trial is underway to evaluate a new gene therapy for Duchenne Muscular Dystrophy (DMD). This study focuses on the use of an adeno-associated viral vector serotype 8 containing the human MD1 gene, also known as GNT0004. The trial aims to determine the proper dosage, assess the safety and effectiveness of the treatment, and monitor long-term outcomes in boys with DMD who can still walk. This innovative approach could potentially revolutionize the treatment of this debilitating genetic disorder.

Related diseases and areas:

• Duchenne muscular dystrophy

ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 9 CONTAINING THE HUMAN CTNNB1 GENE

Clinical trials are studying ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 9 CONTAINING THE HUMAN CTNNB1 GENE in children with CTNNB1 syndrome. The main goals are to check safety, tolerability, and early signs of benefit after a single intracerebroventricular treatment. These trials focus on pediatric patients with this rare condition.

Related diseases and areas:

• Neurodevelopmental disorder

Adeno-Associated Viral Vector Serotype 9 Containing The Human Habcd1 Gene

This article provides an overview of a clinical trial investigating the use of SBT101, an adeno-associated viral vector serotype 9 containing the human HABCD1 gene, as a potential gene therapy for adults with adrenomyeloneuropathy (AMN). The study aims to evaluate the safety, tolerability, and efficacy of this innovative treatment approach for a rare genetic disorder affecting the nervous system.

Related diseases and areas:

• Adrenoleukodystrophy

Adeno-Associated Viral Vector Serotype 9 Containing The Human Sulfamidase Gene

This article discusses ongoing clinical trials for a novel gene therapy treatment targeting Mucopolysaccharidosis type IIIA, also known as Sanfilippo A syndrome. The therapy uses an adeno-associated viral vector serotype 9 containing the human sulfamidase gene (AAV9-CAG-coh-SGSH) to potentially address the underlying genetic cause of this rare metabolic disorder. The trials aim to evaluate the safety, tolerability, and initial efficacy of this innovative approach in children with Sanfilippo A syndrome.

Related diseases and areas:

• Mucopolysaccharidosis

Adeno-Associated Viral Vector Serotype 9 Encoding Human Atp7B

This article discusses the clinical trials of UX701, an innovative gene therapy using Adeno-Associated Viral Vector Serotype 9 Encoding Human ATP7B for the treatment of Wilson Disease. The study aims to evaluate the safety and efficacy of this groundbreaking approach in managing copper metabolism in adult patients with Wilson Disease. We’ll explore the trial design, eligibility criteria, and potential outcomes of this promising treatment.

Related diseases and areas:

• Hepato-lenticular degeneration

Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human Gba Gene

A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of LY3884961, an innovative gene therapy for patients with Type 1 Gaucher Disease. This open-label, dose-finding study aims to assess the potential of this adeno-associated viral vector therapy in addressing the peripheral manifestations of Gaucher Disease. The trial involves carefully planned dose-finding and expansion periods, offering hope for improved treatment options for individuals living with this rare genetic disorder.

Related diseases and areas:

• Parkinson’s disease
• Chronic hepatitis C
• Gaucher’s disease type I

Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human Grn Gene

This article explores the clinical trials of LY3884963, an innovative gene therapy designed to treat Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). The therapy uses an adeno-associated viral vector to deliver a healthy version of the progranulin gene to patients’ cells. The trials aim to assess the safety, tolerability, and effectiveness of this treatment in potentially slowing or halting the progression of this rare form of dementia.

Related diseases and areas:

• Frontotemporal dementia

Adeno-Associated Viral Vector Serotype Rh10 Containing The Human Cholesterol 24-Hydroxylase Gene

This article discusses a groundbreaking clinical trial investigating the use of AB-1001, a gene therapy drug containing an adeno-associated viral vector with the human cholesterol 24-hydroxylase gene. The study aims to evaluate the safety, tolerability, and preliminary efficacy of this innovative treatment for adults with early manifest Huntington’s Disease (HD). This Phase I/II trial represents a significant step forward in the search for effective treatments for this debilitating genetic disorder.

Related diseases and areas:

• Huntington’s disease

ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE RH10 ENCODING MIRNA AGAINST SOD1 MRNA

Clinical trials are studying ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE RH10 ENCODING MIRNA AGAINST SOD1 MRNA in adults with SOD1 ALS. The main goal is to check safety and tolerability, and to look for early signs of benefit. These trials focus on people with amyotrophic lateral sclerosis linked to SOD1.

Related diseases and areas:

• Amyotrophic lateral sclerosis

Adeno-Associated Viral Vector Serotype S3 Containing Codon-Optimised Expression Cassette Encoding Human Beta-Glucocerebrosidase Variant

This article discusses a clinical trial investigating the long-term safety and effectiveness of FLT201, an innovative gene therapy treatment for Gaucher Disease Type 1. FLT201 is an adeno-associated viral vector containing a modified gene that produces an enzyme crucial for managing the disease. The study, known as GALILEO-2, aims to assess the safety, durability, and various effects of this treatment on patients who have previously received FLT201.

Related diseases and areas:

• Gaucher’s disease type I

Adeno-Associated Virus Serotype 2 Encoding Soluble Cd59

Clinical trials are currently underway to evaluate the effectiveness and safety of a new drug called JNJ-81201887, also known as Adeno-Associated Virus Serotype 2 Encoding Soluble CD59 (AAVCAGsCD59). This innovative treatment is being studied for its potential to slow down the progression of Geographic Atrophy (GA), a severe form of Age-related Macular Degeneration (AMD). The trials aim to assess the drug’s ability to reduce GA lesion growth and its long-term safety profile when administered through intravitreal injection.

Related diseases and areas:

• Dry age-related macular deg…

Adeno-Associated Virus Serotype 8 Expressing The Human Gamma-Sarcoglycan Gene

This article discusses a clinical trial investigating the use of ATA-200, a gene therapy drug, for treating limb-girdle muscular dystrophy type R5 (LGMDR5). The trial aims to evaluate the safety and effectiveness of this innovative treatment approach in pediatric patients. ATA-200 uses a modified virus to deliver a healthy copy of the gamma-sarcoglycan gene, potentially addressing the underlying cause of LGMDR5.

Related diseases and areas:

• Muscular dystrophy

ADENO-ASSOCIATED VIRUS SEROTYPE 9 CONTAINING THE HUMAN GCG GENE

Clinical trials of ADENO-ASSOCIATED VIRUS SEROTYPE 9 CONTAINING THE HUMAN GCG GENE are studying a first-in-human treatment approach in adults with inadequately controlled type 2 diabetes. The trial is designed to check safety and tolerability, and it also looks at laboratory changes and adverse events. It is a Phase 1/2 study with 50 planned participants.

Adeno-Associated Virus Serotype 9 Expressing The Human Fukutin Related Protein And Target Sequence Of The Mir-208A

A groundbreaking clinical trial is underway to evaluate a new gene therapy treatment for patients with limb-girdle muscular dystrophy (LGMDR9). The study focuses on using an adeno-associated virus serotype 9 (AAV9) vector carrying the FKRP gene, known as GNT0006. This trial aims to assess the safety, tolerability, and efficacy of this innovative approach in treating LGMDR9, offering hope for patients affected by this rare genetic disorder.

Related diseases and areas:

• Muscular dystrophy

Adeno-Associated Virus Serotype 9 Vector Containing The Human Lamp2 Isoform B Transgene

A groundbreaking clinical trial is underway to assess the effectiveness and safety of a gene therapy treatment for Danon disease. This Phase 2 study focuses on using a specially designed virus, called AAV9.LAMP2B, to deliver a corrective gene to male patients with this rare genetic disorder. The therapy aims to improve heart function and quality of life for those affected by Danon disease.

Related diseases and areas:

• Glycogen storage disease ty…

Adeno-Associated Virus Serotype Rh10 Containing The Human Galc Gene

This article discusses an innovative clinical trial investigating a gene therapy approach for infants with Krabbe disease. The study, known as RESKUE, evaluates the safety and potential benefits of using an adeno-associated virus serotype rh10 containing the human GALC gene (AAVrh10-hGALC) in combination with stem cell transplantation. This groundbreaking research aims to improve treatment outcomes for children affected by this rare genetic disorder.

Related diseases and areas:

• Krabbe’s disease

Adeno-Associated Virus Serotype Rh79 Containing The Human Otc Gene

A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of ECUR-506, a novel gene therapy for male infants under 9 months of age with neonatal-onset Ornithine Transcarbamylase Deficiency (OTCD). This phase I/II study aims to explore the potential of a single intravenous administration of ECUR-506 in treating this rare genetic disorder, offering hope for improved management of OTCD in young patients.

Related diseases and areas:

• Ornithine transcarbamoylase…

Adeno-Associated Virus Vector Containing The Human Rpgr Gene

A groundbreaking clinical trial is underway to assess the safety and effectiveness of AGTC-501, an innovative gene therapy for X-linked Retinitis Pigmentosa (XLRP). This study aims to evaluate the potential of a single subretinal injection of AGTC-501 in improving visual function for male participants with XLRP caused by mutations in the RPGR gene. The trial compares two doses of the therapy against an untreated control group, offering hope for those affected by this rare genetic eye disorder.

Related diseases and areas:

• Retinitis pigmentosa

Adeno-Associated Virus Vector Serotype 8 Containing The Human F9 Gene

This article explores the ongoing clinical trials of REGV131-LNP1265, an innovative gene therapy designed to treat Hemophilia B. This groundbreaking treatment uses an adeno-associated virus vector serotype 8 containing the human F9 gene to potentially improve clotting factor production in patients with this rare bleeding disorder. The trials aim to evaluate the safety, effectiveness, and long-term benefits of this novel approach in adult patients with Hemophilia B.

Related diseases and areas:

• Factor IX deficiency

ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, C-REGION

Clinical trials are investigating ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, C-REGION in people with Stargardt disease. The study aims to assess safety, tolerability, and early signs of benefit, and it focuses on subjects with Stargardt disease type 1 and bi-allelic ABCA4 gene mutations.

Related diseases and areas:

• Stargardt’s disease

ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, N-REGION

Clinical trials are investigating ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, N-REGION in people with Stargardt disease. The studies aim to assess safety, tolerability, and early signs of benefit in patients with confirmed bi-allelic ABCA4 gene mutations.

Related diseases and areas:

• Stargardt’s disease

Adeno‐Associated Viral Vector Serotype 8 Containing The 3′ Human Otoferlin Coding Sequence

A groundbreaking clinical trial is underway to evaluate the efficacy and safety of a new gene therapy called SENS-501 for children with severe to profound hearing loss caused by mutations in the Otoferlin gene. This Phase I/II trial aims to restore hearing by using an innovative approach involving the injection of a specially designed viral vector into the cochlea. The study focuses on children aged 6 to 31 months and could potentially offer hope for those affected by this rare genetic condition.

Related diseases and areas:

• Deafness bilateral

Adenovirus Associated Viral Vector Serotype 5 Containing The Human Pde6B Gene

This article discusses ongoing clinical trials investigating the use of a novel gene therapy called HORA-PDE6B for treating retinitis pigmentosa (RP) caused by mutations in the PDE6B gene. HORA-PDE6B is an adenovirus-associated viral vector that carries the human PDE6B gene, designed to be administered through a subretinal injection. The trials aim to assess the safety and potential efficacy of this treatment in patients with PDE6B-related retinitis pigmentosa, a rare inherited eye disorder that causes progressive vision loss.

Related diseases and areas:

• Retinitis pigmentosa

Adenovirus Vector Serotype 5 Containing The Vascular Endothelial Growth Factor D Isoform (Preprocessed Short Form)

This article discusses a phase II clinical trial investigating the use of Adenovirus Vector Serotype 5 Containing The Vascular Endothelial Growth Factor D Isoform (AdVEGF-D) as a potential treatment for severe coronary artery disease. The study aims to evaluate the safety and effectiveness of this innovative gene therapy approach for patients with refractory angina who are not suitable candidates for traditional revascularization procedures.

Related diseases and areas:

• Angina pectoris
• Acute lymphocytic leukaemia
• Non-Hodgkin’s lymphoma
• Non-Hodgkin’s lymphoma refr…
• Acute lymphocytic leukaemia…

Adg126

Clinical trials are investigating Adg126 in people with advanced liver cancers. These studies aim to evaluate how well Adg126 works in immunotherapy-based combinations and how safe the treatment is. The main focus is on treatment response, safety, and lab and heart-related checks in adult patients.

Related diseases and areas:

• Hepatocellular carcinoma

ADMILPARANT

Clinical trials are investigating ADMILPARANT in people with lung scarring diseases. These studies are checking whether it can improve breathing test results, and they are also looking at safety and tolerability. The target groups are adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

Related diseases and areas:

• Pulmonary fibrosis
• Idiopathic pulmonary fibrosis

Adrc

Clinical trials are investigating Adrc in people with crypto-glandular perianal fistula. The studies aim to check whether Adrc-based regenerative cell treatments, used with minimal surgery, can improve healing and assess outcomes in adults with this condition.

Related diseases and areas:

• Anal fistula

Adrc001

Clinical trials are investigating Adrc001 in different patient groups, including head and neck cancer survivors with dry mouth, people with perianal fistulas, and patients with hypertrophic scars after burns. These studies are looking at treatment effects, safety, and healing outcomes in Phase 1, Phase 1/2, and Phase 2 trials.

Related diseases and areas:

• Head and neck cancer
• Anal fistula
• Hypertrophic scar
• Dry mouth

Ads-010

A new drug called ADS-010, also known as ARO-DUX4, is being studied in clinical trials for the treatment of Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1). This article will provide information about the ongoing research, including the purpose of the study, who can participate, and what the trial involves.

Related diseases and areas:

• Facioscapulohumeral muscula…

Ads-011

A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of ARO-C3, also known as ADS-011, in treating complement-mediated kidney disease. This Phase 1/2a study aims to assess the drug’s safety, tolerability, and how it behaves in the body of adult patients with this condition. The trial represents a significant step forward in developing new treatments for patients with complement-mediated renal disorders.

Related diseases and areas:

• Immune-mediated renal disorder

Ads-013

A new clinical trial is underway to assess the effects of ARO-MUC5AC Inhalation Solution in patients with asthma and chronic obstructive pulmonary disease (COPD). This phase 1/2a study aims to evaluate the safety, tolerability, efficacy, and pharmacological properties of this innovative RNAi-based therapeutic. The trial involves multiple ascending doses administered to healthy volunteers and patients, with a focus on understanding how this treatment may benefit those with muco-obstructive lung diseases.

Related diseases and areas:

• Chronic obstructive pulmona…
• Asthma

Ads-015

This article discusses the clinical trials of ARO-RAGE (ADS-015), an investigational inhalation solution being studied for the treatment of inflammatory lung disease, particularly asthma. The trials aim to assess the safety, tolerability, and effectiveness of ARO-RAGE in both healthy volunteers and patients with mild to moderate asthma. The study will evaluate different dosages and their effects on lung function and inflammation markers.

Related diseases and areas:

• Asthma

ADS-019

Clinical trials investigating ADS-019 are studying its safety, tolerability, and how it works in adults with type 1 myotonic dystrophy. The trials also look at whether repeated doses may help, especially in people aged 18 to 65 years.

ADX-038

Clinical trials are investigating ADX-038 in adults with complement-mediated kidney disease and geographic atrophy secondary to age-related macular degeneration. These studies are looking at safety, tolerability, and early signs of benefit. Both trials are in Phase 2 and are currently authorised.

Related diseases and areas:

• Immune-mediated renal disorder

ADX-324

Clinical trials are investigating ADX-324 in people with hereditary angioedema (HAE). These studies aim to see whether ADX-324 can help prevent HAE attacks and measure how well it works compared with placebo, along with other trial outcomes in the studied population.

Related diseases and areas:

• Hereditary angioedema

Afamelanotide

Clinical trials are studying Afamelanotide in several patient groups, including early Parkinson’s disease, stroke, erythropoietic protoporphyria, vitiligo, and healthy volunteers. These studies mainly look at safety, efficacy, and how the body handles the treatment. The trials include different phases, from Phase 1 to Phase 4.

Related diseases and areas:

• Vitiligo
• Ischaemic stroke
• Parkinson’s disease
• Nervous system disorder
• Porphyria non-acute

Afamitresgene Autoleucel

Afamitresgene Autoleucel, also known as ADP-A2M4, is an innovative cell therapy being studied in clinical trials for patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. This article explores the ongoing Phase 2 clinical trial, called SPEARHEAD 1, which aims to evaluate the efficacy and safety of this genetically modified T-cell therapy in patients with these rare and challenging cancers.

Related diseases and areas:

• Myxoid liposarcoma
• Round cell liposarcoma
• Synovial sarcoma

Afatinib

Clinical trials investigating Afatinib are studying how well it works and how safe it is in different cancer groups. The main focus is on people with EGFR-mutated lung cancer and some patients with advanced squamous cell carcinoma linked to Fanconi anemia. These studies look at treatment sequences, response rates, and progression-free survival.

Related diseases and areas:

• Oropharyngeal squamous cell…
• Congenital aplastic anaemia
• Laryngeal squamous cell car…
• Non-small cell lung cancer
• Squamous cell carcinoma of …
• Squamous cell carcinoma of …

Aficamten

Clinical trials are studying Aficamten in people with hypertrophic cardiomyopathy, including obstructive and non-obstructive forms. These studies look at how well it works, how safe it is, and how it affects exercise ability, symptoms, and heart function in adults and children.

Related diseases and areas:

• Hypertrophic cardiomyopathy

Afimetoran Besilate Dihydrate

Afimetoran Besilate Dihydrate is a promising new drug being studied in clinical trials for the treatment of active Systemic Lupus Erythematosus (SLE). This article explores the ongoing research into its effectiveness and safety, providing insights into the potential benefits for patients with this challenging autoimmune condition.

Related diseases and areas:

• Systemic lupus erythematosus

Aflibercept

Clinical trials investigating Aflibercept are studying how well it works and how safe it is in different patient groups. Most trials focus on eye diseases such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, while a few studies involve other conditions. These trials include adults and some pediatric patients, and most are Phase 3 studies.

Related diseases and areas:

• Neovascular age-related mac…
• Choroid melanoma
• Retinal vein occlusion
• Retinopathy of prematurity
• Age-related macular degener…
• Choroidal neovascularisation

Afm24

Clinical trials are studying Afm24 in people with advanced and metastatic EGFR-expressing cancers. The research is looking at safety, dose selection, and signs of anti-cancer activity, including in combination with other study drugs. The main goal is to learn whether Afm24 can help these patient groups.

Related diseases and areas:

• Neoplasm malignant